Pursuant to the agreements, Parenteral is authorised to register, supply and distribute Sinovac’s Anflu (seasonal influenza vaccine) and Panflu1 (H1N1 vaccine) to the government of India and private market in India. Currently, the registration process is ongoing in India.
Additionally, Parenteral plans to apply to the Drug Controller General of India (DCGI) for the import approval for the vaccines. The volume, delivery schedule and other specific details about how Sinovac’s vaccines may be marketed and supplied to the government of India and the private market in India have not been determined.
Weidong Yin, chairman, president and CEO at Sinovac, said: “The agreements correspond with Sinovac’s international marketing strategy to partner with established local suppliers to secure regulatory approval and more efficiently facilitate distribution in numerous international markets. We look forward to partnering with Parenteral Biotech to bring our seasonal influenza vaccine and H1N1 vaccine to the people of India.”